Topic
Topic
Sanofi will pay Regeneron $1 billion up front plus up to $7 billion in milestones to co-develop four long-acting antibodies targeting IL-13, IL-4, and related type II inflammation pathways, with REGN…
Long-acting investigational therapy EVO301 showed promise in a proof-of-concept atopic dermatitis study, an early signal that ext…
Immunocore hit target enrollment of 540 patients in the Phase 3 TEBE-AM trial of tebentafusp in HLA-A*02:01-positive advanced mel…
Pfizer advances tilrekimig into pivotal atopic dermatitis and asthma trials on the strength of Phase II AD data, deepening its ty…
AbbVie advances its IL-13-targeting biologic zumilokibart into Phase 3 atopic dermatitis trials, adding a pipeline candidate alon…
AbbVie reports zumilokibart met its primary endpoint in a phase 2 atopic dermatitis trial, advancing a key pipeline asset toward…
Dermatology Times' Q3 2026 review rounds up FDA approvals and clinical readouts in dermatology; the syndicated headline did not i…
Genentech has returned a licensed melanoma drug to Hanmi Pharmaceutical, which now plans Korean clinical trials while seeking a n…